Many transdermal drug delivery systems require the use of adhesives, and current TDD technology advances suggest a bright future for this segment of the medical market.
Two years after the introduction of motion-sickness patches, a nitroglycerin patch to treat angina was approved. Today, TDD systems have reached the limits expected by drug manufacturers 20 years ago. Because of the lipophilic nature of skin, only certain types of drugs are suitable for transdermal delivery.